424870 — ImmuneOncia therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩361bn
- KR₩361bn
- KR₩655m
Annual income statement for ImmuneOncia therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 110 | 655 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Total Operating Expenses | 11,907 | 13,253 |
| Operating Profit | -11,797 | -12,599 |
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | 8,864 | -5,687 |
| Provision for Income Taxes | ||
| Net Income After Taxes | 8,864 | -5,687 |
| Net Income Before Extraordinary Items | ||
| Net Income | 8,864 | -5,687 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | 8,864 | -5,687 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | 121 | -77.9 |